Handelsbanken Fonder’s Vanda Pharmaceuticals VNDA Stock Holding History

Handelsbanken Fonder’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18,500	Closed	-$209K	–	1696
2022 Q1	$209K	Hold	18,500	–	–	﹤0.01%	1623
2021 Q4	$290K	Hold	18,500	–	–	﹤0.01%	1620
2021 Q3	$317K	Buy	18,500 +5,700	+45%	+$99.8K	﹤0.01%	1574
2021 Q2	$275K	Buy	12,800 +200	+2%	+$3.58K	﹤0.01%	1649
2021 Q1	$189K	Hold	12,600	–	–	﹤0.01%	1547
2020 Q4	$166K	Hold	12,600	–	–	﹤0.01%	1534
2020 Q3	$122K	Hold	12,600	–	–	﹤0.01%	1433
2020 Q2	$144K	Buy	+12,600	New	+$143K	﹤0.01%	1408

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Handelsbanken Fonder's VNDA Position: Q2 2022 in Review

Handelsbanken Fonder sold out of Vanda Pharmaceuticals (VNDA) in Q2 2022, closing a stake of 18,500 shares — an estimated $209K sold.

Handelsbanken Fonder first reported a position in VNDA in Q2 2020 and held it in 8 quarters. The position peaked at $317K in Q3 2021. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2022.

Handelsbanken Fonder reported no remaining Vanda Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Handelsbanken Fonder sold 18,500 Vanda Pharmaceuticals shares in Q2 2022, an estimated $209K.
Handelsbanken Fonder first reported a position in Vanda Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Handelsbanken Fonder's Vanda Pharmaceuticals position peaked at $317K in Q3 2021.
173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2022.

Based on Handelsbanken Fonder's 13F filing for Q2 2022, filed 3 Aug 2022.